GSK3B and supranuclear palsy, progressive, 1: Valproate was also assessed because of anti–GSK-3β activity, but did not improve PSP Rating Scale scores in 28 PSP patients over the course of 2 years (ClinicalTrials.gov NCT00385710) (103).